Structure Therapeutics Reports Positive Oral Weight-Loss Data
SAN FRANCISCO — September 8, 2026 Structure Therapeutics reported positive clinical data across its two lead oral small-molecule programs...
metabolic disease
Advertisement
Moonwalk Biosciences Raises $70 Million Series B
SOUTH SAN FRANCISCO and SAN DIEGO — September 8, 2026 Moonwalk Biosciences announced the closing of an oversubscribed $70...
Ascletis Begins U.S. Phase 1 Study of ASC36
Hong Kong, September 8, 2026 Ascletis Pharma Inc. has announced the initiation of a U.S. Phase 1 clinical trial...
Novo Nordisk Reports Positive STEP Young Phase 3 Data
Bagsværd, Denmark — September 7, 2026 Novo Nordisk announced positive first results from the STEP Young Phase 3 trial,...
Gan & Lee and Menarini Advance Bofanglutide in Europe
Beijing, China & Florence, Italy, September 3, 2026 Gan & Lee Pharmaceuticals and The Menarini Group have entered into...
Advertisements
Ascletis Starts Phase III Trial of Oral GLP-1 Drug
Hong Kong, China, August 30, 2026 Ascletis Pharma Inc. announced that the first participant has been dosed in its...
Hanmi Pharm Licenses Obesity Drug HM17321 to Genentech
SEOUL, South Korea, August 24, 2026 Hanmi Pharm announced an exclusive global licensing agreement with Genentech, a member of...
PTC Therapeutics Highlights Sephience PKU Data at SSIEM 2026
Warren, New Jersey, August 24, 2026 PTC Therapeutics, Inc. announced that new clinical and real-world evidence for Sephience™ (sepiapterin)...
Ultragenyx Wins FDA Approval for GENGLYCOS Gene Therapy
Novato, California, August 19, 2026 Ultragenyx Pharmaceutical Inc. has announced that the U.S. Food and Drug Administration (FDA) granted...
Amylyx Pharmaceuticals Reports Positive Phase 3 Results
CAMBRIDGE, Mass., August 18, 2026 Amylyx Pharmaceuticals, Inc. announced positive topline results from the Phase 3 LUCIDITY clinical trial...
Advertisement
